Literature DB >> 9308514

Torsade de pointes and low-dose oral haloperidol.

T Jackson1, L Ditmanson, B Phibbs.   

Abstract

Haloperidol, used to treat patients with psychoses, is considered minimally cardiotoxic. Several cases of torsade de pointes have been reported in association with the use of oral haloperidol. In each of those cases, a prolonged QTc preceded the torsade de pointes episode and thus may be considered a predictor for ventricular arrhythmias in elderly women treated with haloperidol. However, the following case may demonstrate the inability to predict an episode of torsade de pointes with low-dose oral haloperidol use.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308514

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  13 in total

Review 1.  The use of psychotropics in the medically ill.

Authors:  M J Robinson; J L Levenson
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

2.  QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.

Authors:  Adrián LLerena; Roland Berecz; Alfredo de la Rubia; Pedro Dorado
Journal:  Eur J Clin Pharmacol       Date:  2002-06       Impact factor: 2.953

Review 3.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

Review 4.  Antipsychotic agents and QT changes.

Authors:  R Welch; P Chue
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

5.  Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of I(Ca,L).

Authors:  Torsten Christ; Erich Wettwer; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-06-16       Impact factor: 3.000

Review 6.  [Lengthening of QT interval by antipsychotic drugs].

Authors:  W Haverkamp; M Deuschle
Journal:  Nervenarzt       Date:  2006-03       Impact factor: 1.214

7.  Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol.

Authors:  Sean Hennessy; Warren B Bilker; Jill S Knauss; Stephen E Kimmel; David J Margolis; Mary F Morrison; Robert F Reynolds; Dale B Glasser; Brian L Strom
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

Review 8.  Drug-induced cardiovascular disorders.

Authors:  C Aengus Murphy; Henry J Dargie
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Analysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia.

Authors:  Iftekhar D Kalsekar; Eugene H Makela; Karen E Moeller
Journal:  Curr Ther Res Clin Exp       Date:  2003-09

10.  Issues in the management of acute agitation: how much current guidelines consider safety?

Authors:  Bruno Pacciardi; Mauro Mauri; Claudio Cargioli; Simone Belli; Biagio Cotugno; Luca Di Paolo; Stefano Pini
Journal:  Front Psychiatry       Date:  2013-05-07       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.